Despite response rates of 30% after high-dose chemotherapy with autologous hematopoietic stem cell transplant, patients with multiple myeloma are not cured.
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. No dose limiting toxicity was seen. To better standardize the marrow compartment radiation dose, the study was modified such that an additional six patients were treated at a targeted absorbed radiation dose to the red marrow of 40 Gy based on a trace labeled infusion 1 week prior to the therapy. Despite rapid elimination of unbound radiopharmaceutical via kidneys and bladder, no episodes of nephrotoxicity, hemorrhagic cystitis, or delayed radiation nephritis were observed with a median followup of 31 months (range 8.5-44). Median times to ANC40.5 and platelet 420 Â 10 6 /l were 12 and 11 days, respectively, with no graft failures. Overall response rate was 94% including seven very good partial responses and five complete responses. Addition of 153 Sm EDTMP to melphalan conditioning appears to be safe, well-tolerated and worthy of further study. 
Background
Multiple myeloma (MM) is a chemotherapy-responsive, but incurable disease. Standard chemotherapy provides response rates of only 50-70% with a median survival of 30-40 months. 1, 2 McElwain et al 3 demonstrated that dose intensification of melphalan resulted in higher response rates, even in patients who were refractory to standard dose melphalan. High-dose chemotherapy with stem cell transplantation (SCT) has been shown to provide higher response rates (B95%) and longer survival in two randomized studies. 4, 5 Complete response rates have ranged from 19 to 44% after a single autologous SCT, [4] [5] [6] [7] [8] but all patients eventually relapse. The lack of survival benefit with transplants utilizing CD34 selected autologous stem cells 9 and the high incidence of relapse after allogeneic SCT 10, 11 reflect the inadequacy of the current conditioning regimens for eradicating the neoplastic clone in vivo. 153 Samarium ethylenediaminetetramethylenephosphonate ( 153 Sm-EDTMP; Quadramet s ) is a radiopharmaceutical approved for the palliation of pain caused by metastatic bone lesions. The compound consists of 153 Sm, a b emitter of medium energy with a physical half-life of 46.3 h, and EDTMP, a diphosphonate compound, that avidly concentrates in bone. It is chemically and biologically stable and is rapidly cleared from nonosseous tissues (a t 1/2 14 min; b t 1/2 65 min). 153 Sm-EDTMP has a b emission range of 0.5-1.01 mm and emits a 103 keV g photon allowing for g camera imaging studies of the distribution of the radionuclide. 12, 13 Use of low-dose 153 Sm-EDTMP in humans has demonstrated an excellent therapeutic ratio in carcinoma metastatic to bone [14] [15] [16] [17] [18] [19] [20] with myelosuppression as the major dose-limiting toxicity. We aspired to exploit this 'toxicity' in the context of a hematologic malignancy in the SCT setting.
In preclincial studies, Turner et al used a murine model system for MM to evaluate the potential therapeutic efficacy of sequential therapy with 153 Sm-EDTMP, melphalan, and SCT using C57BL/KaLwRij mice and 5T33 murine myeloma cells. Mice receiving combined modality therapy (melphalan and 153 Sm-EDTMP) had median survivals 40% longer than mice receiving melphalan alone and 75% longer than mice receiving no treatment. No nonhematopoetic toxicity was observed. 21 We sought to capitalize on three observations: (1) myeloma cells are radiosensitive; 22, 23 (2) melphalan 200 mg/m 2 is as -if not more -effective as melphalan 140 mg/m 2 with external beam total body irradiation; 24 and (3) 153 Sm-EDTMP provides irradiation to the marrow since it localizes to bone and bony trabeculae. 18, 25, 26 We postulated that the use of 153 Sm-EDTMP in association with high-dose melphalan would be safe, but more effective than standard conditioning regimens for MM patients. The standard myeloablative dose of melphalan 200 mg/m 2 was employed in addition to escalating doses of 153 Sm-EDTMP. The high affinity of 153 Sm-EDTMP to bone, its rapid clearance from plasma and other tissues, and the localization of the malignant plasma cells within the skeletal bones, particularly in the trabecular bone adjacent to the marrow, all supported this hypothesis. We report the results of the completed Phase I study.
Materials and methods

Patient selection
Patients with MM referred to the Mayo Clinic (Rochester, MN, USA) for high-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) were potentially eligible for this protocol. Between January 2000 and September 2001, 18 such  patients were entered on a phase I study evaluating  153 Sm  EDTMP, followed by melphalan 200 mg/m 2 with autologous stem cell support. Eligibility criteria included: Durie and Salmon criteria Stage II or III at diagnosis of MM; age greater than 18 years; Eastern Cooperative Oncology Group performance status less than or equal to 2; direct bilirubin less than or equal to 2.0 mg/dl; alkaline phosphatase less than or equal to 2.5 times the institutional normal; serum creatinine less than or equal to 3.0 mg/dl; cardiac left ventricular ejection fraction greater than or equal to 45%; a lung diffusing capacity of oxygen of greater than or equal to 50%; a forced vital capacity of greater than or equal to 50%; and a forced expiratory volume of greater than or equal to 50%. Patients were also required to have greater than or equal to 2 Â 10 6 CD34 cells/kg available for infusion after high-dose therapy. No bisphosphonate drugs were allowed within 2 weeks prior to treatment. Patients were informed of the nature of this Phase I study and signed a protocol-specific consent form (MC9981) approved by the Institutional Review Board of the Mayo Clinic.
Study design
The original Phase I design was to treat patients with fixed dose melphalan in conjunction with escalating dose levels of 153 Sm-EDTMP based on a modified Fibonacci design. The four dose levels were 6, 12, 19.6, and 30 mCi/kg and were based on patients' actual weight. Three patients were entered at a given dose level and observed for at least 28 days to assess toxicity. Dose escalation was allowed if none of three or no more than one of six patients experienced dose-limiting toxicity (DLT). The maximally tolerated dose was defined at that dose at which fewer than two of six patients experienced DLT. Though no DLT occurred in the first 12 patients, who were treated with or up to 30 mCi/kg, the decision was made to stop the phase I escalation based on weight due to the variable red marrow biodistribution. In order to better standardize the marrow compartment radiation dose, an additional six patients were treated at a targeted absorbed radiation dose to the red marrow of 40 Gy based on a trace labeled infusion one week prior to the therapy (Figure 1 ).
With the exception of engraftment, toxicity was defined according to National Cancer Institute Common Toxicity Criteria, version 2.0 toxicity criteria, including its bone marrow toxicity criteria. The Eastern Cooperative Oncology Group Autologous Bone Marrow Toxicity Criteria were used to define engraftment toxicity. DLT was defined as any toxicity of grade 3 or greater, with the following exceptions: vomiting, fatigue, alopecia, libido, amenorrhea, nausea, febrile neutropenia, infection, anorexia, depression, anxiety, and cytopenias. For the case of stomatitis, greater than or equal to grade 4 toxicity was regarded a DLT. A stipulation for radiation toxicity was also made; 20 Gy to any organ other than bone surfaces or red marrow was also defined as a DLT. For engraftment according to the Eastern Cooperative Oncology Group Autologous Bone Marrow Toxicity Criteria, grade 3 toxicity was defined as absolute neutrophil count (ANC) less than 0.5 Â 10 9 /l or platelets less than 1010 9 /l 4-8 weeks after PBSC infusion. The protocol also required that there be no further dose escalation above that level at which engraftment did not occur by day 35. Engraftment of granulocytes and platelets was defined as maintenance of respective counts of 0.5 Â 10 9 /l and 20 Â 10 9 /l for 3 consecutive days without transfusion support. The first day of the 3 consecutive days was considered the day of engraftment.
For the purposes of toxicity reporting, each patient's treatment course was divided into two: the samarium period and the melphalan period ( Figure 1 ). The samarium period included the day of the samarium infusion up until the day of the melphalan infusion, and the melphalan period included the period of time from the melphalan infusion until the time of their dismissal from Transplant Center. These definitions of intervals were used for all toxicities with the exception of myelosuppression. From the standpoint of hematopoietic toxicity, the samarium period was extended to 4 days after the melphalan infusion (3 days after the peripheral blood stem cell infusion) because myelosuppression from melphalan would not be expected until about 5 days after administration.
Drug administration, biodistribution, and dosimetry
The 153 Sm-EDTMP was shipped frozen, thawed, and infused intravenously over 10 min for the first two dose levels and over
Figure 1
Schema for therapy and definitions of toxicity monitoring periods. n Tracer dose was administered only to the last six patients on study. The first 12 patients were treated strictly based on actual body weight.
Phase I study 153 Sm-EDTMP and melphalan as conditioning regimen A Dispenzieri et al 30 min for subsequent levels. For the last six patients enrolled, an additional step incorporating a biodistribution study was included ( Figure 1 ).
153 Sm-EDTMP (30 mCi tracer dose) was injected intravenously. Patients subsequently had two quantitative whole-body g camera images obtained: shortly following injection (10-min scan) and at 24 h (30-min scan). The acquisition window for the whole-body g camera scan was 103 keV (710%). The 153 Sm-EDTMP administered activity was based on the 153 Sm bone uptake values over the 24 h. The dose to achieve 40 Gy to the red marrow was calculated using the following equation, which was derived from the red marrow calculations carried out on the prior patients dosed on a weight basis: mCi 153 Sm ¼ 14.58((1/24 h % uptake) ((63.9 heightcm)À7777.2) þ 524.7). Patients were eligible for a therapeutic dose of the 153 Sm-EDTMP as long as the dose to be administered was calculated to be less than 4000 mCi (or 30 mCi/kg). This restriction was based on two concerns: (1) during the escalation phase, no patient had received more than 4000 mCi or 30 mCi/ kg; and (2) such patients would potentially be subject to high doses of bladder radiation.
The therapeutic dose of 153 Sm-EDTMP was given on average 7 days after the biodistribution dose in the six patients who had a biodistribution study. The therapeutic dose of 153 Sm-EDTMP was administered at the Mayo Clinic General Clinical Research Center in a lead-lined room, and patients were monitored there for urine output and for initial dosimetry studies. Before administration of therapeutic 153 Sm-EDTMP, patients were given oral fluids and were started on one half normal saline þ 20 mEq KCl at 100-200 cm 3 /h. At 4 h after the 153 Sm-EDTMP infusion 20 mg of furosemide was administered, and intravenous fluids were increased to or maintained at 200 cm 3 /h for 24 h after 153 Sm-EDTMP infusion. Furosemide was used as needed to maintain urine output at greater than 300 cm 3 /2 h, and patients were instructed to void every 2 h while awake and every 4 h through the first night.
Blood samples for drug clearance were taken at 0, 0.5, 1, 4, 48, and 72-120 h. g camera imaging was carried out at 0, 4, 24, 48, and 72-120 h post-153 Sm-EDTMP infusion. Patients were dismissed from the General Clinical Research Center after the 48-h imaging. At 9 days post-153 Sm-EDTMP infusion and prior to the high-dose melphalan and PBSCT, the patients had the residual whole body 153 Sm measured using an ionization chamber probe and converted to mCi using standard imaged just after the patient. The probe was placed 20 feet away from the patient and a 10-min count with a 40% window centered at 103 keV. Immediately following the patient measurement a standard of 57 Co was counted using the same times, windows and distance. In addition, a 1-min background count was obtained. The remaining radioactivity in the patient was calculated using the whole-body counts, the standard activity, and the standard counts. The blood and the whole-body fraction of injected activity (FIA) were obtained by dividing the measured activity by the injected activity and the clearance plotted over time. We estimated that a cutoff of 3.6 mCi or less of 153 Sm-EDTMP remaining was safe to reinfuse the PBSC based on prior 131 I-labeled monoclonal antibody experience (personal communication with Dr Press, University of Washington). 27 The assumptions and equations for the conversion follow. Ci h/67.4 ¼ 3.6 mCi. Therefore, patients only received their melphalan once their whole-body radiation was less than 3.6 mCi (median time, 11 days). Melphalan 200 mg/m 2 was administered i.v. over 1 h on day À1 and PBSC were infused on day 0. Patients received GM-CSF 500 mg subcutaneously beginning on day 6 post-PBSC infusion. The GM-CSF was not discontinued before the absolute neutrophil count was greater than 500/ml on 2 consecutive days. Patients received antibiotic prophylaxis including fluconazole, a quinolone, penicillin, and valcyclovir and were treated on an outpatient basis as tolerated. Central parenteral nutrition, narcotics, i.v. antibiotics, transfusions, and hospitalization were used when clinically necessary.
Response definitions
Response criteria were based on those published by the IBMTR/ ABMTR 28 and include the following response criteria: complete response (CR) or continuous CR (cCR), partial response (PR) or continuous PR (cPR), minimal response (MR) and progressive disease (PD) and relapse (Rel). Modifications of the IBMTR criteria used in this protocol are as follows. Patients meeting the new SWOG definition of very good partial response (VGPR), which is typically immunofixation positive disease, were separated from the PR category. To be considered VGPR, a patient must have greater than or equal to 90% reduction of myeloma protein from serum, urine M-spike to be less than or equal to100 mg/24 h, and less than or equal to 5% bone marrow plasma cells in the absence of bony progression. Protein requirements for response were verified on 2 consecutive determinations separated by at least 4 weeks. Duration of follow-up and survival were calculated from the date of study registration. Follow-up is through 10 February 2004.
Results
Patient information
Patient characteristics are listed in Table 1 . Eight (44%) of patients were treated for relapsed disease, seven untested relapse and one with resistant relapse. Two patients (11%) were transplanted for primary refractory myeloma. In total, 17% of patients had a high plasma cell labeling (41.0%) index prior to transplant. Median number of bone marrow plasma cells at transplant was 20%. All patients had myelomatous bone disease. One patient had a treatment-related myelodysplastic syndrome and severe neutropenia before study entry.
Three patients were treated at each of the first four dose levels ( Table 2 ). There was marked variability in the radiation dose delivered to the red marrow and skeleton. Therefore, the trial was temporarily suspended and an additional six patients were treated based on the bone uptake of 153 Sm-EDTMP at 24 h. The
target red marrow dose of 40 Gy was achieved by administering doses ranging from 12 to 27 mCi/kg. Results of radioisotope distribution measurements are described in Table 2 .
Hematopoietic toxicity
The median time between administration of the 153 Sm-EDTMP and of the high-dose melphalan was 11 days, range 7-12 days. As shown in Table 3 , all patients had severe myelosuppression (ANC o0.5 Â 10 9 and platelets o20 Â 10 9 /l after the full treatment regimen. There was myelosuppression from the single agent 153 Sm-EDTMP. By the day of the stem cell infusion, the median (range) WBC, ANC, and platelet counts were 1.5 Â 10 9 /l (0.2-3.2), 1.4 Â 10 9 /l (0-3.1), and 70 Â 10 9 /l (10-155), respectively. By day 3 post-PBSCT, which was a median of 15 days postsamarium and 4 days after the melphalan, the median WBC, ANC, and platelet counts were already 0.55, 0.43, and 33 Â 10 9 /l. By day 3 post-PBSCT, four patients required packed red blood cell transfusions and three platelet transfusions. Two of these patients were treated at the 40 Gy target level.
The time to neutrophil and platelet engraftment and the duration of cytopenias are shown in Table 3 . There was no significant difference in time to neutrophil engraftment among the groups. There was a trend towards delayed platelet engraftment and increased platelet transfusion requirement in the 30 mCi/kg cohort, but not in 40 Gy targeted group. These values are comparable to those of 107 patients treated at our Transplant Center, who received melphalan 200 mg/m 2 alone as their conditioning regimen. In this control group, the median time to a platelet count of 50 was 19 days, with a range of 10-23 days excluding the 8% of patients who did not achieve a platelet count of 50 by day 100 (data not shown). The duration of neutropenia was longer than expected for a control group due to the premelphalan myelosuppression. At the higher dose levels, there was a trend toward earlier and deeper myelosuppression. Despite the slightly prolonged neutropenia, there was not a higher than expected incidence of infection in our study cohort (see below). Table 2 shows the doses of 153 Sm-EDTMP administered and the number of patients treated at each dose level. Table 4 shows all the toxicity attributable to the single agent 153 Sm-EDTMP alone. With the exception of myelosuppression, the toxicity of the 153 Sm-EDTMP was minimal. An occasional patient experienced Phase I study 153 Sm-EDTMP and melphalan as conditioning regimen A Dispenzieri et al grade 1 anorexia, diarrhea, headache, or fatigue. The most common nonhematologic toxicity was nausea (seven patients or 39%). One patient had grade 3 emesis. There was transient asymptomatic hypocalcemia in 78% of patients.
Estimation of the MTD
As expected during the high-dose melphalan period, nearly all patients had diarrhea, nausea vomiting, fatigue, and electrolyte abnormalities. Table 5 enumerates the grade 3 and 4 toxicities. Nearly, all patients had grade 3 or 4 myelosuppression. Despite the slightly prolonged neutropenia in the study group, nine patients had febrile neutropenia and 10 patients had 11 infections: seven line associated bacteremias, two cases of C. difficile colitis, one cellulitis, and one herpes zoster. No patient required intubation, and no patient died. Four patients had microscopic hematuria o100 red blood cells per high powered field during their transplant course. In all instances, the hematuria occurred during periods of platelet count less than 50 Â 10 9 /l. None had gross hematuria. With a median of 30.1 months of follow-up, none have developed microangiopathy or radiation nephritis. None of the observed toxicities were beyond what we observed in patients contemporaneously treated with single agent melphalan 200 mg/m 2 as their PBSCT conditioning regimen.
No dose-limiting toxicities were observed during either period. One patient in the 30 mCi/kg cohort had grade 3 pulmonary toxicity, that is, she had transient hypoxia requiring oxygen by nasal canula. This toxicity could not clearly be Table 3 Time to severe granulocytopenia and thrombocytopenia and to engraftment Dose, mCi/kg (number of patients) All (18) 6 (3) 12 ( Number of transfusions, median (range) Red blood cells
Plts, platelets; ANC, absolute neutrophil count. a One patient had a pre-existing myelodysplastic syndrome and had a baseline platelet count and ANC of 129 Â 10 /l in one patient. c One platelet transfusion is either one apheresis product or 6 units of random donor platelets. Table 5 Grade 3-4 adverse events a related to transplant regimen (numbers of affected patients) Phase I study 153 Sm-EDTMP and melphalan as conditioning regimen A Dispenzieri et al attributed to the study drug since she had severe COPD at baseline, with baseline grade 2 'toxicities' of dyspnea, FEV1, DLCO, and hypoxia.
Response to therapy
Median follow-up for all patients and of surviving patients is 31 months (range 8.6-44) and 37 months, range 28-44 months, respectively. All 18 patients have been assessed for response (Table 6 ). Five patients (28%) achieved a complete response and another 28% achieved a very good partial response. Two patients continued in very good partial response. There were four (22%) partial responses and another continued partial response. One patient had only a 25% reduction in his paraprotein and was considered to have a minimal response. Median duration on study was 11 months (range 3.4-43 months). Five patients remain on study and in continuous response at a median follow-up of 40 months (range 28-43). Six were removed from study because of progressive disease at a median of 15.1 months (range 7.7-27). Another seven patients went onto a maintenance therapy program at a median of 4 months after study entry; follow-up for this subset of patients has been 31 months (range 8.6-42). Six patients have died at a median of 21 months (range 8.6-35 months) due to myeloma.
Discussion
We have shown that we can safely deliver 40 Gy to the red marrow using 153 Sm-EDTMP. High-dose 153 Sm-EDTMP can be incorporated into a conditioning regimen with full dose melphalan (200 mg/m 2 ) without higher than expected toxicity. 24, 29 Our regimen supplants total body irradiation and allows for administration of approximately 40% higher dose of melphalan that would be used typically in a combined melphalan-total body irradiation conditioning regimen. Though the original design defined dose levels on fixed doses of the radiopharmaceutical determined by body weight, we found that this approach resulted in an erratic biodistribution. By using information from a tracer dose of 153 Sm-EDTMP (30 mCi) to estimate dose of radiation to be absorbed by the red marrow after administration of a therapeutic dose (1023-2010 mCi), there was less variability in the red marrow dose. Though the criteria for maximum tolerated dose was not reached (ie grade III to IV regimen-related toxicity in more than one of six or fewer participants treated), we halted further escalation at the 40 Gray level based on data by Sykes et al. 30, 31 These authors found irreversible bone marrow microenvironment damage at bone marrow doses higher than 40 Gy; therefore, the biodistribution targeted dose of 40 Gy will be used in Phase II studies.
There are several reasons to believe that the approach of combining skeletal targeted irradiation with myeloablative chemotherapy and hematopoietic stem cell salvage might lead to an improved response rate and longer disease-free survival. The first is that myeloma cells are radiosensitive and even locally radiocurable. 22, 23 Barlogie et al treated MM patients with various doses of melphalan with and without TBI in the 1980s. He demonstrated that higher response rates were achieved using SCT with melphalan 140 mg/m 2 and TBI 850 cGy than with melphalan 90-140 mg/m 2 alone (nonrandomized comparisons). 32 A nonrandomized, 33 and later a randomized comparison 24 between melphalan 140 mg/m 2 with TBI and melphalan 200 mg/m 2 has demonstrated response equivalency between these two regimens and lower morbidity associated with the latter. In the case of CML and AML higher doses of radiation (TBI) decreases the risk of relapse albeit at the expense of greater normal organ toxicity and nonmalignancy related mortality, negating any survival benefit. 34 Experience with therapeutic radioisotopes in humans has been growing rapidly in the past decades. The two most widely investigated modalities within this field include radiolabeled diphosponates to treat osteoblastic bone metastases and radiolabeled antibody therapy to treat CD20 positive hematologic malignancies. [35] [36] [37] Use of 153 Sm-EDTMP in humans has consistently demonstrated an excellent therapeutic ratio. [14] [15] [16] [17] [18] [19] [20] Both we 38 and others 26 have safely used escalated doses of 153 Sm-EDTMP without concomitant chemotherapy but with 40, 41 The difference in toxicity profile may have to do with our program of aggressive hydration schedule, the different retention times of the two agents, or the different emission path lengths of the respective isotopes.
Larger numbers of patients and randomized controlled trials will be required to define whether the approach of targeted radiotherapy, high-dose chemotherapy, and hematopoietic stem support is superior to standard therapies. Our overall response rate of 94%, excluding the one minimal response, and the combined complete response and very good response rate of 67% are encouraging. Although an assessment of efficacy was not a primary objective of this dose-finding study, the preliminary results are encouraging. Progression-free survival of patients treated on this investigational protocol was not assessed because nearly half were taken off study to enroll on investigational maintenance protocols.
The use of a bone seeking radiolabeled isotope offers several advantages over that of a radiolabeled antibody. The former offers a faster clearance from the blood and other normal organs, less nonhematopoietic tissue toxicity and a reduced likelihood of cell internalization. The high affinity of 153 Sm-EDTMP to bone, its rapid clearance from plasma and other tissues, and the localization of the malignant clones of MM to the bone marrow would suggest that our strategy should be safe and potentially more effective than standard conditioning regimens.
In summary, our current study has demonstrated that substantially greater doses of radiation can be delivered to hematopoietic tissues as compared to other organs. The toxicity of this supplemental radiation has not been appreciably greater than that of melphalan 200 mg/m 2 alone. Overall, this approach offers the possibility of augmenting antimyeloma therapy without increasing toxicity, thus potentially improving the response rate and progression free survival in patients with MM. The results of this trial are encouraging and the Phase II trial is nearing completion.
